Your session is about to expire
← Back to Search
Calcium Channel Blocker and Angiotensin II Receptor Blocker Combination
Azor-Treatment A for High Blood Pressure (AMORE Trial)
Phase 4
Waitlist Available
Led By Bobby V Khan, MD, PhD
Research Sponsored by InVasc Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 weeks
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
Approved for 20 Other Conditions
Drug Has Already Been Approved
No Placebo-Only Group
Summary
The purpose of the study is to compare the effects of Azor (a combination of amlodipine and olmesartan) with Hyzaar ( a combination of losartan and hydrochlorothiazide) on the thin lining on the inside of blood vessels. These cells help keep blood vessels healthy and blood pressure normal.
Eligible Conditions
- High Blood Pressure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 25 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Central Aortic Pressure (CAP)
Secondary study objectives
Blood pressure control
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Azor-Treatment AActive Control1 Intervention
Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
Group II: Hyzaar-Treatment Arm BActive Control1 Intervention
Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
Find a Location
Who is running the clinical trial?
InVasc Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
151 Total Patients Enrolled
Bobby V Khan, MD, PhDPrincipal InvestigatorDirector, Atlanta Clinical Research Centers
Keith C Ferdinand, MDStudy DirectorAtlanta Clinical Research Centers
Share this study with friends
Copy Link
Messenger